Concepts (190)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cost-Benefit Analysis | 31 | 2023 | 454 | 7.530 |
Why?
|
| Health Policy | 7 | 2024 | 180 | 2.760 |
Why?
|
| Medicare Part C | 3 | 2022 | 6 | 2.620 |
Why?
|
| Delivery of Health Care | 5 | 2023 | 426 | 2.570 |
Why?
|
| Quality-Adjusted Life Years | 19 | 2023 | 138 | 2.430 |
Why?
|
| Research Design | 4 | 2020 | 594 | 1.670 |
Why?
|
| Models, Economic | 5 | 2020 | 60 | 1.610 |
Why?
|
| Policy Making | 3 | 2020 | 62 | 1.470 |
Why?
|
| Papillomavirus Vaccines | 3 | 2022 | 58 | 1.160 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 316 | 1.160 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 301 | 1.150 |
Why?
|
| Pandemics | 3 | 2020 | 740 | 1.080 |
Why?
|
| Bariatric Surgery | 2 | 2018 | 194 | 1.070 |
Why?
|
| Health Care Costs | 7 | 2023 | 238 | 1.060 |
Why?
|
| Obesity, Morbid | 2 | 2018 | 225 | 1.050 |
Why?
|
| Decision Making | 4 | 2019 | 642 | 1.030 |
Why?
|
| Mass Screening | 3 | 2022 | 618 | 1.010 |
Why?
|
| Global Health | 4 | 2021 | 193 | 0.970 |
Why?
|
| Public Policy | 1 | 2024 | 52 | 0.950 |
Why?
|
| United States | 17 | 2023 | 6672 | 0.940 |
Why?
|
| Checklist | 2 | 2023 | 57 | 0.920 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2022 | 275 | 0.850 |
Why?
|
| Early Detection of Cancer | 3 | 2022 | 394 | 0.840 |
Why?
|
| Cost of Illness | 2 | 2020 | 150 | 0.830 |
Why?
|
| Nutrition Policy | 3 | 2023 | 12 | 0.830 |
Why?
|
| Cardiovascular Diseases | 3 | 2023 | 827 | 0.830 |
Why?
|
| Papillomavirus Infections | 2 | 2022 | 239 | 0.820 |
Why?
|
| Humans | 47 | 2024 | 86644 | 0.800 |
Why?
|
| Health Facilities | 1 | 2021 | 38 | 0.790 |
Why?
|
| Obesity | 5 | 2023 | 963 | 0.790 |
Why?
|
| Prostatic Neoplasms | 2 | 2022 | 1721 | 0.780 |
Why?
|
| Critical Pathways | 1 | 2020 | 35 | 0.750 |
Why?
|
| Quarantine | 1 | 2020 | 8 | 0.740 |
Why?
|
| Meat Products | 1 | 2019 | 7 | 0.720 |
Why?
|
| Quality Indicators, Health Care | 1 | 2021 | 144 | 0.720 |
Why?
|
| Neoplasms | 4 | 2023 | 2898 | 0.710 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 172 | 0.700 |
Why?
|
| Network Meta-Analysis | 1 | 2019 | 7 | 0.690 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 176 | 0.680 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 806 | 0.670 |
Why?
|
| Population Health | 1 | 2019 | 33 | 0.660 |
Why?
|
| Comparative Effectiveness Research | 1 | 2019 | 53 | 0.650 |
Why?
|
| Publications | 1 | 2018 | 27 | 0.640 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 45 | 0.640 |
Why?
|
| Quality Improvement | 1 | 2020 | 428 | 0.570 |
Why?
|
| Motivation | 1 | 2019 | 287 | 0.550 |
Why?
|
| Uncertainty | 4 | 2023 | 71 | 0.540 |
Why?
|
| Insurance Coverage | 3 | 2023 | 117 | 0.520 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 394 | 0.500 |
Why?
|
| Pancreatic Neoplasms | 1 | 2020 | 645 | 0.490 |
Why?
|
| Coronary Artery Disease | 1 | 2019 | 350 | 0.490 |
Why?
|
| Nutrition Surveys | 4 | 2023 | 114 | 0.480 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 582 | 0.440 |
Why?
|
| Hepatitis C | 1 | 2014 | 208 | 0.420 |
Why?
|
| Developing Countries | 3 | 2023 | 71 | 0.420 |
Why?
|
| Health Priorities | 3 | 2020 | 23 | 0.390 |
Why?
|
| Health Expenditures | 3 | 2022 | 86 | 0.390 |
Why?
|
| Antiviral Agents | 1 | 2014 | 510 | 0.380 |
Why?
|
| Technology Assessment, Biomedical | 2 | 2020 | 27 | 0.370 |
Why?
|
| Prostate-Specific Antigen | 2 | 2022 | 353 | 0.370 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 1621 | 0.350 |
Why?
|
| Orphan Drug Production | 2 | 2019 | 3 | 0.350 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 1373 | 0.330 |
Why?
|
| Registries | 4 | 2021 | 702 | 0.320 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2022 | 238 | 0.320 |
Why?
|
| Male | 9 | 2023 | 40966 | 0.320 |
Why?
|
| Aged | 6 | 2023 | 18415 | 0.310 |
Why?
|
| Female | 11 | 2023 | 44533 | 0.310 |
Why?
|
| Adult | 8 | 2023 | 25648 | 0.280 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 2262 | 0.280 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 2903 | 0.280 |
Why?
|
| Young Adult | 5 | 2023 | 5976 | 0.250 |
Why?
|
| Africa South of the Sahara | 2 | 2020 | 21 | 0.240 |
Why?
|
| Medicare Part D | 1 | 2023 | 10 | 0.230 |
Why?
|
| Vaccination | 2 | 2022 | 254 | 0.230 |
Why?
|
| Anti-Obesity Agents | 1 | 2023 | 14 | 0.230 |
Why?
|
| Efficiency | 1 | 2023 | 40 | 0.230 |
Why?
|
| Incidence | 2 | 2019 | 1577 | 0.220 |
Why?
|
| Risk Factors | 3 | 2023 | 5417 | 0.220 |
Why?
|
| Middle Aged | 7 | 2023 | 25028 | 0.210 |
Why?
|
| Drug Costs | 2 | 2020 | 62 | 0.210 |
Why?
|
| Food Labeling | 1 | 2021 | 8 | 0.200 |
Why?
|
| Quality of Life | 3 | 2021 | 1585 | 0.200 |
Why?
|
| Psychoses, Substance-Induced | 1 | 2020 | 6 | 0.190 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2020 | 13 | 0.190 |
Why?
|
| Marijuana Abuse | 1 | 2020 | 26 | 0.190 |
Why?
|
| Advisory Committees | 1 | 2021 | 90 | 0.190 |
Why?
|
| Age Factors | 2 | 2022 | 1851 | 0.190 |
Why?
|
| Social Conditions | 1 | 2020 | 8 | 0.190 |
Why?
|
| Actuarial Analysis | 1 | 2020 | 66 | 0.190 |
Why?
|
| Social Control, Formal | 1 | 2020 | 12 | 0.190 |
Why?
|
| Regional Medical Programs | 1 | 2020 | 5 | 0.190 |
Why?
|
| Noncommunicable Diseases | 1 | 2020 | 5 | 0.180 |
Why?
|
| Costs and Cost Analysis | 1 | 2020 | 153 | 0.180 |
Why?
|
| Betacoronavirus | 2 | 2020 | 258 | 0.180 |
Why?
|
| Fear | 1 | 2020 | 78 | 0.180 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2019 | 3 | 0.180 |
Why?
|
| Databases, Factual | 2 | 2020 | 814 | 0.180 |
Why?
|
| Markov Chains | 3 | 2014 | 125 | 0.180 |
Why?
|
| Health Behavior | 1 | 2021 | 183 | 0.180 |
Why?
|
| Cardiology | 1 | 2021 | 123 | 0.180 |
Why?
|
| Computer Simulation | 1 | 2024 | 1078 | 0.170 |
Why?
|
| Aged, 80 and over | 2 | 2022 | 6509 | 0.170 |
Why?
|
| Professional Review Organizations | 1 | 2018 | 1 | 0.170 |
Why?
|
| Probability | 1 | 2019 | 355 | 0.170 |
Why?
|
| Cost Sharing | 1 | 2018 | 14 | 0.160 |
Why?
|
| Gross Domestic Product | 1 | 2018 | 2 | 0.160 |
Why?
|
| Life Tables | 1 | 2018 | 48 | 0.160 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2019 | 58 | 0.160 |
Why?
|
| Disease Management | 1 | 2020 | 327 | 0.160 |
Why?
|
| Bibliometrics | 1 | 2018 | 37 | 0.160 |
Why?
|
| Consensus | 1 | 2019 | 335 | 0.160 |
Why?
|
| Income | 1 | 2018 | 75 | 0.160 |
Why?
|
| Bayes Theorem | 1 | 2019 | 361 | 0.150 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2019 | 229 | 0.150 |
Why?
|
| Research | 1 | 2018 | 253 | 0.150 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 141 | 0.150 |
Why?
|
| Treatment Outcome | 2 | 2020 | 7993 | 0.150 |
Why?
|
| Coronary Artery Bypass | 1 | 2019 | 228 | 0.150 |
Why?
|
| Diffusion of Innovation | 1 | 2017 | 71 | 0.150 |
Why?
|
| Adolescent | 3 | 2020 | 8981 | 0.140 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 859 | 0.140 |
Why?
|
| Egypt | 1 | 2014 | 13 | 0.130 |
Why?
|
| Survival Analysis | 1 | 2019 | 1538 | 0.130 |
Why?
|
| Uridine Monophosphate | 1 | 2014 | 9 | 0.130 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 2501 | 0.130 |
Why?
|
| Sofosbuvir | 1 | 2014 | 18 | 0.130 |
Why?
|
| Decision Trees | 1 | 2014 | 63 | 0.130 |
Why?
|
| Body Mass Index | 1 | 2018 | 770 | 0.130 |
Why?
|
| Ribavirin | 1 | 2014 | 57 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2019 | 376 | 0.120 |
Why?
|
| Interferons | 1 | 2014 | 133 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 376 | 0.120 |
Why?
|
| Triamcinolone Acetonide | 1 | 2013 | 8 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1169 | 0.110 |
Why?
|
| Laser Coagulation | 1 | 2013 | 54 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2019 | 2767 | 0.110 |
Why?
|
| Macular Edema | 1 | 2013 | 50 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 927 | 0.110 |
Why?
|
| Cloprostenol | 1 | 2012 | 1 | 0.110 |
Why?
|
| Trabeculectomy | 1 | 2012 | 3 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 894 | 0.110 |
Why?
|
| Diabetic Retinopathy | 1 | 2013 | 87 | 0.110 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2012 | 17 | 0.100 |
Why?
|
| Glucocorticoids | 1 | 2013 | 352 | 0.100 |
Why?
|
| Prevalence | 1 | 2014 | 1239 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 311 | 0.090 |
Why?
|
| Laser Therapy | 1 | 2012 | 142 | 0.090 |
Why?
|
| Disease Progression | 1 | 2014 | 1531 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 2601 | 0.080 |
Why?
|
| Time Factors | 1 | 2017 | 5210 | 0.080 |
Why?
|
| Antihypertensive Agents | 1 | 2012 | 521 | 0.080 |
Why?
|
| Child | 1 | 2016 | 6927 | 0.060 |
Why?
|
| Energy Intake | 1 | 2023 | 98 | 0.060 |
Why?
|
| Mexican Americans | 1 | 2022 | 63 | 0.050 |
Why?
|
| Dietary Sugars | 1 | 2021 | 8 | 0.050 |
Why?
|
| British Columbia | 1 | 2020 | 7 | 0.050 |
Why?
|
| Cost Savings | 1 | 2021 | 66 | 0.050 |
Why?
|
| Cannabis | 1 | 2020 | 34 | 0.050 |
Why?
|
| Diet | 1 | 2023 | 443 | 0.050 |
Why?
|
| China | 1 | 2020 | 228 | 0.040 |
Why?
|
| Adolescent Behavior | 1 | 2020 | 106 | 0.040 |
Why?
|
| Disabled Persons | 1 | 2020 | 67 | 0.040 |
Why?
|
| Health Planning | 1 | 2018 | 17 | 0.040 |
Why?
|
| Psychotic Disorders | 1 | 2020 | 184 | 0.040 |
Why?
|
| Public Health | 1 | 2020 | 129 | 0.040 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2018 | 10 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2020 | 502 | 0.040 |
Why?
|
| Health Services | 1 | 2018 | 55 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2018 | 70 | 0.040 |
Why?
|
| Global Burden of Disease | 1 | 2018 | 10 | 0.040 |
Why?
|
| Data Accuracy | 1 | 2018 | 31 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2018 | 136 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2018 | 297 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2022 | 1143 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2018 | 839 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2018 | 482 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2018 | 339 | 0.030 |
Why?
|
| Ranibizumab | 1 | 2013 | 15 | 0.030 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2013 | 16 | 0.030 |
Why?
|
| Financing, Personal | 1 | 2013 | 21 | 0.030 |
Why?
|
| Intravitreal Injections | 1 | 2013 | 67 | 0.030 |
Why?
|
| Pregnancy | 1 | 2020 | 2894 | 0.030 |
Why?
|
| Travoprost | 1 | 2012 | 1 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2013 | 281 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 407 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2012 | 129 | 0.020 |
Why?
|
| Health Status | 1 | 2012 | 360 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1686 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2013 | 930 | 0.020 |
Why?
|